A Randomized Phase II Study Of Perioperative Mfolfirinox Versus Gemcitabine/Nab-Paclitaxel As Therapy For Resectable Pancreatic Adenocarcinoma.
Posted Date: May 15, 2019
- Investigator: Davendra Sohal
- Type of Study: Drug
to compare the effects of two different combinations of FDA-approved chemotherapy drugs. These two combinations are called mFOLFIRINOX (oxaliplatin, irinotecan, and fluorouracil) and gemcitabine plus nab-paclitaxel. These chemotherapy drugs will be given before and after surgery. The addition of the
Criteria:
To Be Eligible For This Study, Patients Must Have Pancreatic Cancer That Can Be Removed By Surgery.
Keywords:
Pancreatic, S1505, Resectable, Cancer, Gastrointestinal
For More Information:
Uc Cancer Center
513-584-7698
kastla@uc.edu